Sermorelin for Sale: A Listing Read Like a Pharmacy Label

A sermorelin for sale listing is easier to judge than most peptide listings, because sermorelin has something almost nothing else in this market has: a regulatory paper trail you can pull up yourself. It was an approved US drug, sold as Geref by EMD Serono, and that means there is a real standard to hold a listing against rather than a vague sense of what looks professional.

Five things on a listing are checkable in a couple of minutes. The form the material ships in, the quantity on the label, a lot number that ties the vial to a document, the scope of the testing behind that document, and whether the seller stays inside the claims it is allowed to make. Everything else on a product page is design.

The listing we link is Ascension's Sermorelin (10 MG). It publishes a lot number and a certificate, which puts it ahead of listings that publish a stock photograph and a purity figure with nothing behind it. We earn a commission if you buy through our link, which is set out on our affiliate disclosure page, and it is why the sections below spend as long on what the certificate omits as on what it reports.

Geref carried two applications at FDA. NDA 019863 was the diagnostic product, 0.05 mg per ampoule, with submissions running from May 1991. NDA 020443 was the therapeutic version, 0.5 mg and 1 mg per vial, approved on 26 September 1997. Both are recorded as discontinued, and the FDA product record carries the Federal Register determination that the product was not discontinued or withdrawn for safety or effectiveness reasons. You can read both entries on Drugs@FDA.

What that leaves is a compound with an approval history and no current US label. DailyMed, which holds the structured product labels for everything currently marketed in the States, returns zero sermorelin entries. So the leaflet, the approved indication, the contraindication list and the adverse event reporting route that a pharmacy label carries do not exist in a current form for anything you can buy today.

A research listing does not replace that, and the honest thing is to say so rather than dress the listing up. What a good listing can do is publish the few facts a laboratory measured, tie them to a specific batch, and leave the reader able to check them. That is a smaller promise than a label, and it is the only promise on offer outside a prescription.

One certificate is linked to this product, and it belongs to a single lot. MZ Biolabs in Tucson, Arizona ran the analysis on 7 February 2026 and signed it on the thirteenth. The method was HPLC with ultraviolet and mass spectrometric detection, four peaks were detected, and the analyst named on the document is Ken Pendarvis.

The two numbers that matter are 99.79% purity and 11.31 mg of material measured against a 10 mg label. The second one is worth pausing on. Vials are filled to hit a minimum, and this lot came in 13.1% over its stated quantity, which changes the real cost per milligram without changing the price. It is a property of this lot, not a promise about the vial that reaches your door.

The identity side checks out independently. The sequence printed on the certificate converts to YADAIFTNSYRKVLGQLSARKLLQDIMSR, twenty-nine residues with a C-terminal amide, which is canonical GHRH(1-29). The formula and mass the vendor lists, C149H246N44O42S and 3357.9 g/mol, match PubChem CID 16132413 exactly. The right compound is described on the page.

The certificate reports purity and quantity. There is no endotoxin test on it and no sterility test on it. For a lyophilised powder that buyers reconstitute and inject, those are the two assays that speak to what happens after the powder is dissolved, and neither was run on this lot.

That gap is not a technicality invented by reviewers. FDA's own stated reason for placing several peptides in Category 2 of its bulk substances list is the risk for immunogenicity, which it attributes to the potential for aggregation and peptide-related impurities. A purity figure of 99.79% by HPLC speaks to the first half of that sentence. Endotoxin and sterility testing speak to the part a purity assay cannot reach.

Say it as a property of the batch rather than a verdict on the seller. This lot's certificate covers purity and quantity. A different lot may carry a different scope, and the only way to know is to open the document attached to the lot number on the vial you receive and read the assay list at the top.

List price is $99.99. The site price is $72.00, and the code PEPTIDEDECK brings a single vial to $36.00. On the 10 mg label that is $3.60 per milligram. On the 11.31 mg this lot actually assayed it is $3.18 per milligram, which is the figure to carry into any comparison, with the caveat that it describes one lot.

Quantity tiers work separately from the code: three per cent, five per cent and ten per cent come off the list price at higher volumes, and free shipping begins at $250. A single discounted vial is nowhere near that line, so if postage is charged, fold it into the per-milligram figure before deciding the price was good. We do not claim the tiers and the code combine, because that is not documented anywhere we can point to. Build the cart both ways and read the total.

A large discount off a list price the seller also set is not evidence of a bargain, which is a point we make at more length in our sermorelin coupon guide. What the per-milligram figure is good for is comparing two sellers of the same compound. It is not a way to decide which compound is worth buying.

The fastest way to disqualify a listing is to read what it promises. A research supplier cannot lawfully make human-use claims, and a listing that describes what the compound will do for your sleep, your body composition or your energy has told you something about the operation behind it before you have looked at a single document.

There is a second reason to be sceptical of those claims here, and it is not regulatory. The approved indications for Geref were paediatric growth hormone deficiency and pituitary diagnostics. PubMed holds 332 papers that mention sermorelin, three with it in the title, and zero for sermorelin together with anti-aging. ClinicalTrials.gov registers no studies naming the compound at all. The clinic market sells adult vitality; the literature covers children with growth hormone deficiency and a diagnostic test of pituitary function.

The three title papers are worth knowing so you can recognise a citation that has been stretched. PMID 18046908 is a 2006 discussion piece in Clinical Interventions in Aging about adult-onset growth hormone insufficiency. PMID 18031173 is a 1999 BioDrugs review of use in children with idiopathic growth hormone deficiency. The third, from 2021, concerns recurrent glioma and has nothing to do with anything a buyer is asking about.

Sermorelin sits in a category of one inside this portfolio. It is absent from FDA's Category 2 bulk substances list in every section, while ibutamoren mesylate sits there under both 503A and 503B, ipamorelin acetate, GHRP-2 and GHRP-6 are listed, and compounds such as BPC-157, MOTS-c and epitalon were nominated and then withdrawn. Because sermorelin acetate was a component of an approved drug product, a compounding pharmacy working under section 503A can use it on a prescription.

That makes the choice in front of a reader a genuine comparison rather than a foregone conclusion. One route costs $36.00 and arrives with a certificate covering purity and quantity. The other costs a consultation, bloodwork and time, and ends with a labelled, pharmacist-dispensed preparation and a record of what you were given. Our guide to how to get a sermorelin prescription works through the second route, and the supplier checklist works through the first.